{"name":"Piramal Pharma","slug":"piramal","ticker":"PPLPHARMA.NS","exchange":"NSE","domain":"piramal.com","description":"Piramal Group is an Indian multinational conglomerate that has presence across various sectors such as healthcare, life sciences, drug discovery, financial services, alternative investment and real estate. It headquartered in Mumbai, Maharashtra, India.","hq":"Mumbai, India","founded":0,"employees":"5476","ceo":"Nandini Piramal","sector":"CDMO / Complex Generics / Consumer Healthcare","stockPrice":143.77,"stockChange":2.73,"stockChangePercent":1.94,"marketCap":"$190.4B","metrics":{"revenue":88713797632,"revenueGrowth":-2.9,"grossMargin":61,"rdSpend":0,"netIncome":-1636099968,"cash":7440600064,"dividendYield":10,"peRatio":64.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lupin's Atorvastatin patent cliff ($1.2B at risk)","drug":"Lupin's Atorvastatin","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Piramal's Omeprazole patent cliff ($500M at risk)","drug":"Piramal's Omeprazole","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Piramal Pharma reports strong Q3 FY2024 results","summary":"Piramal Pharma announced its Q3 FY2024 earnings, with revenue growth of 12% YoY and EBITDA margin expansion of 150bps.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Piramal Pharma partners with Biocon Biologics for biosimilar development","summary":"Piramal Pharma and Biocon Biologics announced a partnership to develop and commercialize biosimilars in the US and other key markets.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1EaTJxR1ZoM29WMHBSOUlHQ3J3V1ZjYXloeUhxVG9YSTdpWU1Wd191N0t2SGNfaEhPcE1hMEhzREduWThKUmhWWkl6SVFHR1ZIY3FsY0h3Uks4T2lobXdvZ3lHRUFWQUMycFd5OUU2N1Q?oc=5","date":"2026-04-04","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Makers Laboratories Limited (MAKERSL.BO) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore","headline":"Makers Laboratories Limited (MAKERSL.BO) Analyst insights, Price targets and Recommendations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNR3oxM2VvMllWQkx6Z1NwRHZuaEgzbTFPeW9YNUV4ak9vdGxzUkVKNmFyZU5uYWQ2NU1VcC1IeWJpazZiNEZwRUJIYXVfTDBvV1lCV2ZoZnpONDNJZENKRFJ0NmdYTHhqVkxSMjZVQzh0Sm5USGduTXc5YnpudjdWbDI3eEVvWFlSUDc3Q1ZrTHpPMWxlOUE?oc=5","date":"2026-03-25","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press - Yahoo! Finance Canada","headline":"Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press - ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQQ1RUYzN1S01tVVZDaXB4M0dpVl9adXVRTTFIejRoTlNnZkZzZ0xjR2xrWFVNZGx6UzdadHZONjVYMWpvdk9Ha3BJblVZX0xVNFFZZWJKZ3hVcjd5X3ZrdlE0VlNzYl9RSkNNT1pvNFU2eC1YVUFXNi1hMk9DZEYyXzZ0TnBncWliekhycUlR?oc=5","date":"2026-03-16","type":"pipeline","source":"Yahoo Finance","summary":"Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch - Yahoo Finance","headline":"Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE1oYnBfc0xNY1FJUG1yMDExWExwSk5BQ3I3TXdqV19UdF9ZYmpBT1N6MVZZWFNZR2pFUW81cTVRLVExdnNja3BTUjdmZmlYRVpoeUtSUEhITHQ?oc=5","date":"2026-02-04","type":"pipeline","source":"Yahoo Finance UK","summary":"Viyash Scientific Limited (VIYASH.NS) stock price, news, quote and history - Yahoo Finance UK","headline":"Viyash Scientific Limited (VIYASH.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE9wMEZQRjNVa1Yxc1Ftc24xN1g3RXN4Y0lqNUlIX3lZVzdSNlBlM1hhemJQVzh3a0FjRnFhYi1pTGc3SEFHNWUtZEZVRTh3dVVBLVQzalJ2ZlY?oc=5","date":"2026-01-24","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Viyash Scientific Limited (VIYASH.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Viyash Scientific Limited (VIYASH.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQMzRVUzdBYzdsMVlhcmZQcHRwbTZsLWRsM1VYUWF3TExlSE5oSFFjdm5FbHdISFViczNueFdYbWNKVlA1MXU0QjlZazdUQndTXzFHSDhPVThFb2lKXzVQMXRjQ29FZHhXZm5tMlM0cVBVNnhKQWhwNDdMNGpiazhvQTlBTUFDdG5kZFZjYWJPQQ?oc=5","date":"2025-11-05","type":"earnings","source":"Yahoo Finance","summary":"Piramal Pharma Limited Announces Results for Q2 and H1 FY26 - Yahoo Finance","headline":"Piramal Pharma Limited Announces Results for Q2 and H1 FY26","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPa0N4ZnBzeUdCNGM1dm0tNmZTU3JtSloxMXJkVXR0VVk1dlBVLXpOQ285bF9QaG5uV1RldVgwM1M4YnpzOFQtcTdkVERQTlpJMnNCLVd4Szg1Vk1kcHBqTi1QRHY5WXo1RWlmQ3pKbnBWQjYxbV9BWDRZaWVXUkh1OQ?oc=5","date":"2025-07-03","type":"pipeline","source":"Yahoo Finance","summary":"Carlyle to sell up to 10% stake in Piramal Pharma, Moneycontrol reports - Yahoo Finance","headline":"Carlyle to sell up to 10% stake in Piramal Pharma, Moneycontrol reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFB3czJ5Q1dIeUdNb0c4RFdiNUZMZm9rZlFCa3BpVWhESUdTcnF5MGR0Mm4yamE1NllmaVM0Um5WbUpMSXdpc0M4ZHllUjVNTnBzRU9DcWlXNGgwdw?oc=5","date":"2025-05-27","type":"pipeline","source":"Yahoo Finance Singapore","summary":"COHANCE LIFESCIENCES LTD (COHANCE.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"COHANCE LIFESCIENCES LTD (COHANCE.NS) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Lupin's Atorvastatin","drugSlug":"atorvastatin","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Piramal's Omeprazole","drugSlug":"omeprazole","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Lupin","Aurobindo Pharma","Cipla"],"therapeuticFocus":["Cardiovascular","Gastrointestinal"],"financials":null,"yahoo":{"currentPrice":143.77,"previousClose":141.04,"fiftyTwoWeekHigh":228.45,"fiftyTwoWeekLow":132.3,"fiftyTwoWeekRange":"132.3 - 228.45","fiftyDayAverage":152.03,"twoHundredDayAverage":180.7,"beta":0.19,"enterpriseValue":227556638720,"forwardPE":64.3,"priceToBook":2.36,"priceToSales":2.15,"enterpriseToRevenue":2.56,"enterpriseToEbitda":23.85,"pegRatio":0,"ebitda":9542899712,"ebitdaMargin":10.8,"freeCashflow":0,"operatingCashflow":0,"totalDebt":48509501440,"debtToEquity":60.1,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":10,"targetMeanPrice":200.1,"targetHighPrice":265,"targetLowPrice":150,"dividendRate":0.14,"payoutRatio":0.15,"fiveYearAvgDividendYield":0,"exDividendDate":1752624000,"insiderHeldPercent":54.6,"institutionHeldPercent":20.4,"sharesOutstanding":1323367386,"floatShares":608756077,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-1.24,"epsForward":2.24,"revenuePerShare":67.05,"bookValue":61.03,"officers":[{"age":45,"name":"Ms. Nandini Ajay Piramal","title":"Executive Chairperson"},{"age":52,"name":"Mr. Vivek  Valsaraj","title":"CFO & Executive Director"},{"age":47,"name":"Mr. Peter Daniel DeYoung","title":"CEO of Piramal Global Pharma & Director"},{"age":61,"name":"Vinay  Agarwal","title":"Senior Vice President of Operations"},{"age":51,"name":"Mr. Viral  Gandhi","title":"President & Group CIO of Piramal Group"},{"age":null,"name":"Mr. Gagan  Borana","title":"Head of Investor Relations & Sustainability"},{"age":null,"name":"Mr. Sandeep K. Rathod","title":"General Counsel"},{"age":null,"name":"Ms. Pratibha  Mishra","title":"Interim Company Secretary & Compliance Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.piramalpharma.com","phone":"91 22 3802 3000"}}